Sorrento Therapeutics und mRNA
Seite 2 von 7 Neuester Beitrag: 19.12.22 23:55 | ||||
| Eröffnet am: | 18.08.21 12:33 | von: Meikel 1 2 . | Anzahl Beiträge: | 162 |
| Neuester Beitrag: | 19.12.22 23:55 | von: Bullish_Hope | Leser gesamt: | 40.517 |
| Forum: | Hot-Stocks | Leser heute: | 10 | |
| Bewertet mit: |  | |||
| Seite: < 1 | | 3 | 4 | 5 | 6 | 7 7 > | ||||
bei Seeking Alpha
Sizing Up Sorrento Therapeutics. AGAIN
https://seekingalpha.com/article/...ng-up-sorrento-therapeutics-again
vor allem auch in den Kommentaren viele Infos...
da gibts viel auszuwerten...
18 Jul. 2021, 5:31 PM
Comments (28)
|
Here is a wider overview. With the Mexican COVI-STIX EUA approval and DOD CRADA for 4 potential near term EUA's it's time for another Sorrento program update! WITH OVER 64 PROGRAMS in the portfolio there is a lot happening investors want to know more about! Karolinska, Mayo Clinic, Mt. Sinai, ACEA, SmartPharm partnerships and acquisitions. Sorrento has become a well-funded world-class holding company!
Phase 3, close to EUA or close to market (13 programs)
1. Abivertinib NSCLC NDA filed China
2. Abivertinib NSCLC ph.3 completed US
3. PD-L1 SCLC partnered
4. Erbitux biosimilar
5. Xolair biosimilar
6. Remicade biosimilar
7. SP-102 sciatica
8. RTX Osteo Arthritis
9. RTX cancer pain
10. Covi-Stix EUA application(approval in Mexico!)DOD CRADA
11. Covi-Trace EUA application
12. Sofusa Enbrel
13. Cynviloq (part of PSS lawsuit)
Phase 2 (13 programs)
1. Seprehvir Oncolytic virus
2. Covi-MSC EUA potential
3. Covi-AMG EUA potential DOD CRADA
4. COVIDROPS EUA potential DOD CRADA
5. Covi-Track EUA pre-validation DOD CRADA
6. PD-L1 partnered
7. Herceptin delivery partnered
8. Abivertinib Lymphoma
9. Abivertinib Covid 19 EUA potential as soon as August
10. Abivertinib prostate cancer ph.2 IND
11. Abivertinib Lupus ph.2 IND
12. Abivertinib hairy cell leukemia
13. CD47 partnered
Phase 1, IND filed or pre-IND (38+ programs)
1. Seprehvec Oncolytic Virus
2. CD 38 CAR-T ph.1
3. CEA CAR-T ph.1
4. CD38 DAR-T IND
5. BCMA DAR-T pre-IND
6. PD-L1(C/DAR-T) pre-IND
7. CyCART-19 partnered
8. Covi-GeneMab pre-IND $34 million DARPA funding
9. PD1-GeneMab pre-IND
10. ERT (Enzyme Replacement Therapy) several pre IND programs
11. IL2Teff pre-IND
12. IL2Treg pre-IND
13. Sofusa anti-PD1 and anti-CTLA4
14. TNF-a (Enbrel) ph.1
15. CTLA-4 (Yervoy)
16. CD47 ph.1 basket trial partnered
17. TROP2 pre-IND partnered
18. BCMA ADC pre-IND
19. ROR1 ADC pre-IND
20. CD25 ADNAB pre-IND
21. CD20 ADNAB (Rituxan) IIT-ph.1
22. VEGF(Avastin) ADNAB IIT-ph.1
23. PD-L1 ADNAB pre-IND
24. VEGFR2 ADNAB pre-IND
25. CBD immune diseases pre-IND
26. CBD insomnia pre-IND
27. CBD Parkinsons pre-IND
28. CBD CNS diseases pre-IND
29. PD-L1 CAR-NK partnered
30. CD38 CAR-NK to be partnered
31. CD38 ADC AL Amyloidosis
32. AC0058 ph.1b lupus
33. AC0058 pre-IND MS
34. AC0939 pre-IND CNS indications
35. A166 HER2 ADC phase 1
36. Karolinska off-the-shelf DAR-NK pre-IND
37. 1,000,000+ small molecule library
38. Twenty quadrillion antibody library
FUNDING? Sorrento has invested wisely and has 8.2 million shares of ImmunityBio, 20 million shares of Celularity and 35% of ImmuneOncia. These are worth many hundreds of millions and the PSS lawsuit will soon be settled with very large potential gains. And it has many attractive programs to partner for upfront, milestone and royalty payments! The first of many EUA's will produce revenues within weeks(Mexico). Huge portfolio AND huge assets! Sorrento is in the early days of becoming(or being acquired by...) a Big Pharma IMO!
18 Jul. 2021, 8:49 PM
Premium
Marketplace
Comments (603)
|
@DonF Agree, some *seemingly* positive news, but there is zero and I mean ZERO communication with investors. Why not hold quarterly calls like a standup publicly traded company? Why does Ji think the black box method is better? It impacts share price and volatility which lands squarely on Ji's lap in terms of fault. The canard of "manipulation, shorts, MM's, hedge funds, etc." Is complete BS...Ji could stop it with a clear, cogent, and thoughtful communication strategy vs. the PR barrage he seems to love. Hint hint: the MM's selling covered calls, lending to shorts, hedge fund shorts, and day traders love it too...why on earth does he choose this method of corporate comms?
FAZIT:
scheint so zu sein das die Unternehmenskommunikation
von Sorrento sehr schwierig ist,,, bzw. mit den Investoren
nicht stattfindet...?
Aug. 03, 2021 9:47 AM ETSorrento Therapeutics, Inc. (SRNE)By: Jonathan M Block, SA
https://seekingalpha.com/news/...-mexico-for-covid-therapies-vaccines
Aug. 11, 2021 9:05 AM ETDyadic International, Inc. (DYAI), SRNEBy: Mamta Mayani, SA News Editor3 Comments
Close-up of bottles of COVID-19 vaccine
peterschreiber.media/iStock via Getty Images
Dyadic International (NASDAQ:DYAI) soars 22% premarket after signing a binding term sheet to enter into a License Agreement with Sorrento Therapeutics (NASDAQ:SRNE) to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic’s lead COVID-19 vaccine candidate, DYAI-100, produced using DYAI's proprietary and patented C1-cell protein production platform.
“The license agreement, when executed, contemplates an up-front payment of $10 million in cash and stock, up to $4 million in reimbursements for preclinical and clinical development costs incurred by Dyadic for the development and advancement of our proprietary DYAI-100 vaccine, up to $33 million in milestone payments and ongoing royalties following commercialization. All future development costs related to this license will be incurred by Sorrento,” said Mark Emalfarb, Dyadic’s President and CEO.
Upon execution, Sorrento will obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries.
Seite 8
Seite 12
Seite 30 !
https://investors.sorrentotherapeutics.com/...-47fc-b20f-5cab2e10b54e
https://investors.sorrentotherapeutics.com/...-4bf9-b935-7bb8c24fb39a
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Sorrento Therapeutics |
Sorrento ist ein interessanter Wert...
schwierig in der Kommunikation,...
aber aktuell gut in der Pipeline
noch nicht gehypt,...eine "Holding"
mals sehen was aus den Phase 3 noch kommt...
bin schon investiert
aber noch überschaubar
1 Produkt ist am Markt
jetzt auch bei den Krankenkassen gelistet...
aber Sorrento benötigt auch noch Geld...
noch sehr spekulativ...
Sorrento Announces That COVISTIX (COVID-19 Virus Rapid Antigen Detection Test) Has Received a CE Mark and Registration of the Device
October 20, 2021 at 1:37 PM EDT
COVISTIX has received CE mark and marketing authorization from FAMHP (Federal Agency for Medicines and Health Products) that enables Sorrento to sell this device in all territories that accept the Qarad EC-Rep (Belgium) CE Mark for commercialization.
Distribution contracts are being negotiated
...dann warten wir mal wenn die Verträge fertig sind...
..."Sorrento verfügt derzeit über eine Kapazität von 30.000.000 COVISTIX-Tests pro Monat
und baut derzeit seine Fertigungskapazitäten in den USA aus. Das Unternehmen geht
davon aus, im ersten Quartal 2022 eine vollautomatisierte Montagelinie mit einer Kapazität
von 6.000.000 COVISTIX-Einheiten pro Monat in Betrieb zu nehmen. In Abhängigkeit von der Nachfrage in den USA und weltweit könnte diese Kapazität im Jahr 2022 potenziell auf über 100 Millionen monatlich erhöht werden.
mal sehen wann es losgeht...
Jan 4, 2022 from 5:00 PM to 5:30 PM EST
H.C. Wainwright BioConnect Virtual Conference
December 27, 2021 at 9:00 AM EST
Download PDF
SAN DIEGO and MEXICO CITY, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today its subsidiary, Sorrento Therapeutics Mexico (“Sorrento Mexico”), has executed a second contract with a large distributor for the sale and distribution of up to 10 million COVISTIX tests for the Mexican market. Sorrento previously announced that Sorrento Mexico had signed a contract with a leading local distributor for up to 5 million COVISTIX tests in Mexico, bringing the total number of tests to 15 million to date.
Since its commercial launch in July, the COVISTIX COVID-19 Virus Rapid Antigen Detection Test has been well received for its ease of use and rapid generation of results. In addition, independent clinical testing by a leading Mexican national institute demonstrated a very high sensitivity of around 90% when tested in an all-comers population, including asymptomatic COVID-19 virus carriers, while the other commercial rapid COVID-19 virus antigen tests evaluated failed to achieve sensitivity above 62%. The rapid COVISTIX test provides a much needed tool to mass screen the population for sports events, school attendance and all other family and social gatherings as well as for businesses.
Sorrento Therapeutics erhält FDA-Zulassung für Studie mit Seprehvec zur Behandlung rezidivierter, refraktärer solider Tumore
Falls schon gepostet, habe es noch nicht gesehen, einfach löschen.
https://ch.marketscreener.com/kurs/aktie/...ezidivierter-re-37377385/
Den Markt scheint es wenig zu interessieren da aktuell der Focus auf C19 liegt.
Seit geraumer Zeit geht es kontinuierlich nach Süden.
Optionen
| Boardmail an "Bullish_Hope" |
Wertpapier: Sorrento Therapeutics |
Der multimodale, mehrgleisige Ansatz von Sorrento zur Bekämpfung von Krebs wird durch seine umfangreichen Immunonkologie-Plattformen ermöglicht, darunter wichtige Vermögenswerte wie vollständig humane Antikörper („G-MAB-Bibliothek“), immunzelluläre Therapien („DAR-T“), Antikörper-Wirkstoff-Konjugate („ADCs“) und onkolytische Viren („Seprehvec“). Sorrento entwickelt außerdem potenzielle antivirale Therapien und Impfstoffe gegen Coronaviren, darunter Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC und COVIDROPS; und diagnostische Testlösungen, einschließlich COVITRACK und COVISTIX.
Das Engagement von Sorrento für lebensverbessernde Therapien für Patienten zeigt sich auch in unseren Bemühungen, ein erstklassiges (TRPV1-Agonist) nicht-opioides Schmerzmanagement-Kleinmolekül Resiniferatoxin („RTX“) und SP-102 (10 mg, Dexamethason-Natriumphosphat-viskoses Gel) (SEMDEXA), eine neuartige, viskose Gelformulierung eines weit verbreiteten Kortikosteroids für epidurale Injektionen zur Behandlung von lumbosakralen radikulären Schmerzen oder Ischias und zur Kommerzialisierung von ZTlido (topisches Lidocain-System) 1,8 % zur Behandlung von postherpetische Neuralgie (PHN).
RTX hat die Zulassung für eine Phase-II-Studie für hartnäckige Schmerzen im Zusammenhang mit Krebs und eine Phase-II-Studie bei Osteoarthritis-Patienten. SEMDEXA gab statistisch hochsignifikante positive Top-Line-Ergebnisse aus seinem Phase-III-Pivotal-Trial-C.L.E.A.R-Programm für sein neuartiges, nicht opioides Produkt zur Behandlung von lumbosakralen radikulären Schmerzen (Ischias) bekannt. ZTlido wurde am 28. Februar 2018 von der FDA zugelassen.
https://finance.yahoo.com/quote/SRNE?p=SRNE
https://www.nasdaq.com/de/market-activity/stocks/...rnings-peg-ratios
https://www.nasdaq.com/de/market-activity/stocks/srne/analyst-research